STOCK TITAN

Certara, Inc. - $CERT STOCK NEWS

Welcome to our dedicated page for Certara news (Ticker: $CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Certara's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Certara's position in the market.

Rhea-AI Summary
Certara's Simcyp group has been awarded two new grants from the FDA to expand its predictive models for drug virtual bioequivalence (VBE) and create a formulation toolbox for topically applied drugs. These capabilities will enable safer, faster, and more cost-effective product development. Virtual bioequivalence (VBE) trial simulations using PBPK modeling can reduce or replace costly and time-consuming clinical trials. The grants will also support the development of a reliable dermal PBPK model for lower risk and more efficient development of generic drug products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none
-
Rhea-AI Summary
Certara, a global leader in biosimulation, reported its financial results for the second quarter of fiscal year 2023. Revenue was $90.5 million, net income was $4.7 million, and adjusted EBITDA was $32.4 million. The company's software business performed well, but lower growth in services due to cautious spending led to a restatement of the 2023 outlook. Certara is updating its full year 2023 guidance with revenue expected in the range of $345 million to $360 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
-
Rhea-AI Summary
Certara, a global leader in Biosimulation, announced that Korea Institute of Toxicology (KIT) will implement Certara’s Pinnacle 21 Enterprise and SEND Explorer software. The software optimizes data analysis and visualization for regulatory compliance and enables scientists to gain scientific insight. Pinnacle 21 Enterprise validates compliance with CDISC standards and has been adopted by FDA and PMDA. SEND Explorer provides advanced viewing and visualization capabilities for nonclinical study data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.72%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.14%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
Certara, Inc.

Nasdaq:CERT

CERT Rankings

CERT Stock Data

2.82B
109.07M
2.92%
97.79%
3.55%
Software Publishers
Information
Link
United States of America
PRINCETON

About CERT

certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies. for more information, visit www.certara.com.